On Dec. 20, 2019, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Daiichi Sankyo’s Enhertu for the treatment of adults with unresectable or metastatic HER2-positive breast cancer who had received two or more prior anti-HER2-based regimens in the metastatic setting.